Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prost...(Group cannot be certain that favourable ...)

Date:10/13/2009

Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorite des Marches Financiers.

[1] depending on the countries, Ipsen commercialises Decapeptyl(R) under different brand names (Diphereline(R), Pamorelin(R), Arvekap(R))

    [2] triptorelin pamoate is similar to triptorelin embonate

    For further information:

    Ipsen

    Media

    Didier Veron
    Director, Public Affairs and Corporate Communications
    Tel.: +33-(0)1-58-33-51-16
    Fax:  +33-(0)1-58-33-50-58
    E-mail: didier.veron@ipsen.com

    Financial Community

    David Schilansky
    Investor Relations and Financial Officer
    Tel.: +33-(0)1-58-33-51-30
    Fax:  +33-(0)1-58-33-50-63
    E-mail: david.schilansky@ipsen.com

    Pierre Kemula
    Investor Relations Manager
    Tel.: +33-(0)1-58-33-60-08
    Fax:  +33-(0)1-58-33-50-63
    E-mail: pierre.kemula@ipsen.com

    Debiopharm

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs &
    Communication
    Tel.: +41-(0)21-321-01-11
    Fax:  +41-(0)21-321-01-69
  
'/>"/>
SOURCE  Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award